अApnaFunda
Menu

DIVIS LABORATORIES LIMITED (DIVISLAB)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.82 / 100
Profitability 88Growth 57Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.84 / 100
Price 98Earnings 79FII/DII 76

Passes these screensHigh MomentumDebt-light & profitableConsistent compoundersNear 52-week high

Compare withSUN PHARMACEUTICAL INDUSTRIESTORRENT PHARMACEUTICALSLAURUS LABS

Share price

Closing priceAdjusted for splits and bonus issues.

₹11,565.5 latest close · +71.2% over the last 90 sessions

₹8,000₹10,000₹12,000Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹8,000₹10,000₹12,000Jul 3Sep 4Nov 9

₹11,565.5 month-end · +78.6% over 12 months

₹6,000₹8,000₹10,000₹12,000Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹6,000₹8,000₹10,000₹12,000Nov '25May '26Nov '26

₹11,565.5 month-end · +205.3% over 3 years

₹5,000₹7,500₹10,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹5,000₹7,500₹10,000Nov '23May '25Nov '26

₹11,565.5 month-end · +667.9% since Jan '19

₹5,000₹10,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹5,000₹10,000Jan '19Dec '22Nov '26

52-week range ₹5647.50 to ₹11824.00 · 1-year volatility 25.2%

Was the rally earned?

+79%share price, 1 yearEarnings and multiple

Both mattered.

  • Per-share earnings added 32 points and the multiple added 46 points (P/E 74.6x to 105.0x).
  • The share count barely moved.
Net profit growth: +32 pts. Points of the price return explained by net profit growing (or shrinking).+32 ptsNet profit growthP/E change: +46 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+46 ptsP/E changeShare price: +79%+79%Share priceNet profit growth: +32 pts. Points of the price return explained by net profit growing (or shrinking).+32ProfitP/E change: +46 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+46P/EShare price: +79%+79%Share price
Net profit growth+32 ptsNet profit rose about 27%, which lifts the price.
P/E change+46 ptsThe P/E rose from 74.6x to 105.0x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+205%share price, 3 yearsEarnings and multiple

Both mattered.

  • Per-share earnings added 87 points and the multiple added 118 points (P/E 55.2x to 105.0x).
  • The share count barely moved.
Net profit growth: +87 pts. Points of the price return explained by net profit growing (or shrinking).+87 ptsNet profit growthP/E change: +118 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+118 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +205%+205%Share priceNet profit growth: +87 pts. Points of the price return explained by net profit growing (or shrinking).+87ProfitP/E change: +118 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+118P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +205%+205%Share price
Net profit growth+87 ptsNet profit rose about 60%, which lifts the price.
P/E change+118 ptsThe P/E rose from 55.2x to 105.0x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+137%share price, 5 yearsEarnings and multiple

Both mattered.

  • Per-share earnings added 62 points and the multiple added 76 points (P/E 65.3x to 105.0x).
  • The share count barely moved.
Net profit growth: +62 pts. Points of the price return explained by net profit growing (or shrinking).+62 ptsNet profit growthP/E change: +76 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+76 ptsP/E changeShare price: +137%+137%Share priceNet profit growth: +62 pts. Points of the price return explained by net profit growing (or shrinking).+62ProfitP/E change: +76 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+76P/EShare price: +137%+137%Share price
Net profit growth+62 ptsNet profit rose about 47%, which lifts the price.
P/E change+76 ptsThe P/E rose from 65.3x to 105.0x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-48.8%recovered 2024-09
1-year volatility25.2%annualised
Beta vs sector index0.983-year daily, correlation 0.56
Volume spikes0last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%2020202120222023202420252026−48.1% 0%−20%−40%2020202220242026−48.1%
Largest drawdowns

-48.8% (2021-10 peak to 2023-02 low, recovered 2024-09)

-19.4% (2020-03 peak to 2020-03 low, recovered 2020-04)

-18.5% (2025-07 peak to 2025-09 low, recovered 2026-07)

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

105.0xP/E todayNear its historic high
Against its own history100th percentile
CheapestMedian 59.0xDearest

Usual range 32.2x to 83.9x since 2019-01.

Against Health Technology105.0x vs 37.0x
This company
105.0x
Sector median
37.0x

184% above the Health Technology median.

16.7x46.1x75.5x105.0xJan '19Aug '20Mar '22Oct '23May '25Nov '2616.7x46.1x75.5x105.0xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE77th▲ 4 pts vs a year ago
  • Op. margin99th▲ 11 pts vs a year ago
  • Revenue growth63rd▼ 15 pts vs a year ago
  • EPS growth68th▼ 10 pts vs a year ago
  • Debt/equity ↓97thflat vs a year ago
  • Cash cycle ↓10thflat vs a year ago
  • P/E ↓9th▼ 5 pts vs a year ago
  • 12M momentum87th▲ 9 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~38%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 137.8x, a holder earning 12%/yr needs earnings to grow about 38.3%/yr for 10 years, then trade at 15x.

Delivered9.9%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+28.5 ptsimplied minus delivered
Rank67thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%19%38% Jan 2019Nov 2026 0%19%38% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x40.0%41.2%42.5%
15x37.1%38.3%39.6%
20x33.5%34.7%35.9%

Drag a slider to test other assumptions

Implied: 38.3%/yr

Looking back

  • Jan 2020Price implied 25%/yr; EPS has since grown 10%/yr (7.0 yrs)
  • Jan 2021Price implied 31%/yr; EPS has since grown 11%/yr (6.0 yrs)
  • Jan 2022Price implied 31%/yr; EPS has since grown 5%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹11565.50
P/E
105.0x
ROCE
22.0%
Market Cap
₹3.07L cr
Revenue (TTM)
₹11230 cr
P/S
27.3x
P/B
18.3x
ROE
17.5%
Operating Margin
41.0%
Debt / Equity
0.0x
Promoter Holding
51.9%
12M Momentum
78.6%

52-week range

₹5647.50₹11824.00
96% of the way from its 52-week low to its high

Price risk

1Y volatility
25.2%
Beta vs sector
1-year daily
1.02

Balance sheet & cash

Interest cover
operating profit ÷ interest
100.0x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.89x
Share count, 1Y
unchanged

Are profits backed by cash?

6 of 7checks within range1 near a threshold
Other income reliance10%Within range

Other income as a share of pre-tax profit (trailing twelve months): 9.9%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate25%Within range

Median quarterly effective tax rate over about 2.5 years: 24.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.89xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.89x (cash from operations ₹5,652 cr, net profit ₹6,359 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+3 daysWithin range

Debtor days are above the median of the previous three fiscal years by 3 days (103 vs 100). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress32% of fixed assetsNear threshold

Capital work-in-progress is 32% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+12 days / 2 yrsWithin range

Days payable changed by +12 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, FIIs added 5.3 pts; DIIs trimmed 2.5 pts.
  • The number of shareholders fell from 3.5 lakh to 2.3 lakh (-36%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters51.9%51.9%0.0 pts
FIIs14.8%20.2%+5.3 pts
DIIs21.8%19.3%-2.5 pts
Public and others11.3%8.5%-2.8 pts

Number of shareholders

2.3 lakhshareholders-36% since Dec '23
2.3L2.7L3.1L3.5L Dec '23Jun '24Dec '24Jun '25Dec '25Jun '26
Dec '23: 3.5 lakh
Mar '24: 3.5 lakh
Jun '24: 3.0 lakh
Sep '24: 2.8 lakh
Dec '24: 2.8 lakh
Mar '25: 2.7 lakh
Jun '25: 2.6 lakh
Sep '25: 2.5 lakh
Dec '25: 2.3 lakh
Mar '26: 2.3 lakh
Jun '26: 2.3 lakh
 2.3L2.7L3.1L3.5L Dec '23Dec '24Dec '25Jun '26
Dec '23: 3.5 lakh
Mar '24: 3.5 lakh
Jun '24: 3.0 lakh
Sep '24: 2.8 lakh
Dec '24: 2.8 lakh
Mar '25: 2.7 lakh
Jun '25: 2.6 lakh
Sep '25: 2.5 lakh
Dec '25: 2.3 lakh
Mar '26: 2.3 lakh
Jun '26: 2.3 lakh

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−20.0%typical 12-month return vs the marketBelow the base rate
  • We found 50 past situations where a non-financial company looked like DIVIS LABORATORIES LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −32% to −6% vs the market, against +1% for all non-financial companies in the same months.
  • The analogs' median sat below that base rate (gap −21.3%, 80% range −29.3% to −16.8%), but the matches cluster in only 5 distinct 12-month windows.

Where the 50 outcomes landed

−60%−40%−20%0%+20%+40%
COHANCE · Feb 2025: −78.4% vs market
NAVINFLUOR · Apr 2023: −52.3% vs market
ABBOTINDIA · Apr 2020: −46.5% vs market
BRITANNIA · May 2020: −41.4% vs market
HINDUNILVR · Mar 2023: −40.5% vs market
NESCO · Feb 2020: −39.6% vs market
CRISIL · Dec 2024: −38.5% vs market
PFIZER · Mar 2020: −37.4% vs market
BIOCON · Jun 2020: −36.6% vs market
GLAXO · Mar 2020: −36.3% vs market
DABUR · Mar 2020: −33.2% vs market
IGL · Apr 2020: −33.1% vs market
POLYMED · Oct 2024: −32.2% vs market
PGHH · Mar 2020: −31.3% vs market
ITC · Apr 2023: −30.7% vs market
BATAINDIA · Jan 2020: −30.0% vs market
AFFLE · Jun 2025: −29.1% vs market
GILLETTE · Jun 2025: −28.3% vs market
AJANTPHARM · May 2020: −27.6% vs market
PIDILITIND · Mar 2020: −25.8% vs market
SUMICHEM · Jul 2025: −25.3% vs market
PERSISTENT · Dec 2021: −23.9% vs market
EICHERMOT · Oct 2022: −22.0% vs market
LINDEINDIA · Aug 2023: −21.7% vs market
UNITDSPR · Apr 2025: −20.5% vs market
ASTRAZEN · Apr 2020: −19.4% vs market
DRREDDY · Apr 2020: −17.9% vs market
BAJAJ-AUTO · Mar 2024: −16.9% vs market
NATCOPHARM · Jul 2020: −16.5% vs market
ASIANPAINT · Mar 2020: −15.3% vs market
WHIRLPOOL · Jan 2020: −13.3% vs market
BERGEPAINT · Feb 2020: −11.8% vs market
DMART · Jun 2020: −11.7% vs market
AIAENG · Mar 2023: −9.2% vs market
SCHAEFFLER · Sep 2025: −7.9% vs market
PGHL · Apr 2020: −7.5% vs market
RELAXO · Jan 2020: −6.1% vs market
GRINDWELL · Aug 2022: −5.5% vs market
HAL · May 2024: −4.8% vs market
PIIND · May 2020: −2.4% vs market
SUNPHARMA · Jan 2023: −1.4% vs market
ATUL · Apr 2020: +4.4% vs market
LALPATHLAB · Mar 2020: +7.4% vs market
CUMMINSIND · Oct 2025: +8.3% vs market
SIEMENS · Apr 2023: +14.6% vs market
BALKRISIND · Jul 2020: +14.6% vs market
JUBLFOOD · Jan 2020: +15.1% vs market
HONAUT · Jan 2020: +16.9% vs market
BEL · May 2024: +23.6% vs market
CDSL · Aug 2020: +83.5% vs market
Similar setups −20.0%All companies +1.3%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median
−20.0%
All companies' median
+1.3%
Beat the market
18% vs 51%

50 past situations · 50 companies · 25 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
PIDILITIND
Process Industries		 Mar 2020 75x33% +9%−20% −26%
PFIZER
Health Technology		 Mar 2020 40x27% +21%−12% −37%
PIIND
Process Industries		 May 2020 52x25% +35%−4% −2%
GLAXO
Health Technology		 Mar 2020 47x31% −3%−26% −36%
DABUR
Consumer Non-Durables		 Mar 2020 55x28% +10%−13% −33%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
BEL
Electronic Technology		 May 2024 73x30% +164%0% +24%
ABBOTINDIA
Health Technology		 Apr 2020 82x37% +139%−2% −47%
BRITANNIA
Consumer Non-Durables		 May 2020 70x44% +16%0% −41%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and revenue growth. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to DIVIS LABORATORIES LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

BHARAT ELECTRONICSBEL
Electronic Technology
72%similar
market capvolatility
DR. LAL PATHLABSLALPATHLAB
Health Services
65%similar
revenue growthpromoter holding
EICHER MOTORSEICHERMOT
Consumer Durables
64%similar
market capvolatility
CUMMINS INDIACUMMINSIND
Producer Manufacturing
63%similar
revenuepromoter holding
HDFC ASSET MANAGEMENT COHDFCAMC
Finance
63%similar
promoter holdingdebt/equity
SUN PHARMACEUTICAL INDUSTRIESSUNPHARMA
Health Technology
69%similar
market capROCE
GLAND PHARMAGLAND
Health Technology
62%similar
promoter holdingEPS growth
AJANTA PHARMAAJANTPHARM
Health Technology
59%similar
volatilityrevenue growth

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Feb '22

  1. JulValuationP/E crossed above the 90th percentile of its own history to date (83.3x).
  2. JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
  3. MarPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
  4. DecPriceVolume reached 7.6x its 50-day median on 2025-12-30; price -0.5% that day.
  5. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 3rd quartile).
  6. MayValuationP/E crossed above the 90th percentile of its own history to date (84.9x).
  7. MayPriceVolume reached 6.9x its 50-day median on 2025-05-19; price +4.8% that day.
  8. MarResultsRevenue (TTM) reached a new high of ₹9,078 cr.
Show 22 earlier events
  1. DecResultsYear-on-year EPS growth turned positive.
  2. DecPeer rankMoved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
  3. OctPriceVolume reached 5.8x its 50-day median on 2024-10-09; price +8.0% that day.
  4. SepPriceRegained the 2021-10 peak, 19 months after the low.
  5. SepPriceVolume reached 14.2x its 50-day median on 2024-09-27; price +1.5% that day.
  6. JunValuationP/E crossed above the 90th percentile of its own history to date (76.3x).
  7. JunPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
  8. MayPriceVolume reached 5.6x its 50-day median on 2024-05-27; price +3.2% that day.
  9. NovPriceVolume reached 5.8x its 50-day median on 2023-11-06; price +4.7% that day.
  10. JunResultsYear-on-year EPS growth turned negative.
  11. JunPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
  12. AprPriceVolume reached 12.5x its 50-day median on 2023-04-12; price +9.7% that day.
  13. FebPriceFell 49% from the Oct 2021 peak to the Feb 2023 low.
  14. FebPriceVolume reached 15.6x its 50-day median on 2023-02-03; price -11.7% that day.
  15. NovPriceVolume reached 8.6x its 50-day median on 2022-11-09; price -3.4% that day.
  16. OctValuationP/E fell below the 10th percentile of its own history to date (32.4x).
  17. AugPriceVolume reached 6.2x its 50-day median on 2022-08-12; price -5.6% that day.
  18. JunResultsRevenue (TTM) reached a new high of ₹8,960 cr.
  19. JunValuationP/E fell below the 10th percentile of its own history to date (32.6x).
  20. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
  21. MayPriceVolume reached 13.0x its 50-day median on 2022-05-24; price -6.1% that day.
  22. FebPriceVolume reached 5.7x its 50-day median on 2022-02-11; price -0.5% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-11105.0x₹11230 cr17.5%22.0%0.0x
2026-1088.8x₹11230 cr17.5%22.0%0.0x
2026-0984.3x₹11230 cr17.5%22.0%0.0x
2026-0897.9x₹10560 cr15.3%22.0%0.0x
2026-0783.3x₹10560 cr15.3%22.0%0.0x
2026-0668.0x₹10560 cr15.3%22.0%0.0x
2026-0571.4x₹10314 cr16.6%20.0%0.0x
2026-0469.6x₹10314 cr16.6%20.0%0.0x
2026-0363.7x₹10314 cr16.6%20.0%0.0x
2026-0268.5x₹10029 cr16.6%20.0%0.0x
2026-0164.6x₹10029 cr16.6%20.0%0.0x
2025-1268.3x₹10029 cr16.6%20.0%0.0x
2025-1174.6x₹9652 cr15.4%20.0%0.0x
2025-1077.6x₹9652 cr15.4%20.0%0.0x
2025-0965.5x₹9652 cr15.4%20.0%0.0x
2025-0874.3x₹9360 cr14.6%20.0%0.0x
2025-0779.9x₹9360 cr14.6%20.0%0.0x
2025-0682.5x₹9360 cr14.6%20.0%0.0x
2025-0584.9x₹9078 cr15.2%16.0%0.0x
2025-0478.2x₹9078 cr15.2%16.0%0.0x
2025-0374.2x₹9078 cr15.2%16.0%0.0x
2025-0279.2x₹8614 cr13.5%16.0%0.0x
2025-0180.6x₹8614 cr13.5%16.0%0.0x
2024-1288.2x₹8614 cr13.5%16.0%0.0x
2024-1197.9x₹8185 cr12.3%16.0%0.0x
2024-1093.4x₹8185 cr12.3%16.0%0.0x
2024-0986.3x₹8185 cr12.3%16.0%0.0x
2024-0884.5x₹7845 cr11.8%16.0%0.0x
2024-0781.7x₹7845 cr11.8%16.0%0.0x
2024-0676.3x₹7845 cr11.8%16.0%0.0x
2024-0562.7x₹7768 cr14.3%19.0%0.0x
2024-0458.3x₹7768 cr14.3%19.0%0.0x
2024-0350.2x₹7768 cr14.3%19.0%0.0x
2024-0250.8x₹7768 cr14.3%19.0%0.0x
2024-0153.4x₹7768 cr14.3%19.0%0.0x
2023-1256.8x₹7768 cr14.3%19.0%0.0x
2023-1155.2x₹7768 cr14.3%19.0%0.0x
2023-1049.3x₹7768 cr14.3%19.0%0.0x
2023-0954.8x₹7768 cr14.3%19.0%0.0x
2023-0852.3x₹7768 cr14.3%19.0%0.0x
2023-0753.6x₹7768 cr14.3%19.0%0.0x
2023-0652.2x₹7768 cr14.3%19.0%0.0x
2023-0530.9x₹8960 cr25.2%35.0%0.0x
2023-0429.3x₹8960 cr25.2%35.0%0.0x
2023-0325.3x₹8960 cr25.2%35.0%0.0x
2023-0225.3x₹8960 cr25.2%35.0%0.0x
2023-0129.7x₹8960 cr25.2%35.0%0.0x
2022-1230.6x₹8960 cr25.2%35.0%0.0x
2022-1130.5x₹8960 cr25.2%35.0%0.0x
2022-1032.4x₹8960 cr25.2%35.0%0.0x
2022-0933.2x₹8960 cr25.2%35.0%0.0x
2022-0832.5x₹8960 cr25.2%35.0%0.0x
2022-0734.4x₹8960 cr25.2%35.0%0.0x
2022-0632.6x₹8960 cr25.2%35.0%0.0x
2022-0548.0x₹6969 cr21.3%32.0%0.0x
2022-0460.3x₹6969 cr21.3%32.0%0.0x
2022-0358.9x₹6969 cr21.3%32.0%0.0x
2022-0257.1x₹6969 cr21.3%32.0%0.0x
2022-0154.0x₹6969 cr21.3%32.0%0.0x
2021-1262.6x₹6969 cr21.3%32.0%0.0x
2021-1165.3x₹6969 cr21.3%32.0%0.0x
2021-1068.9x₹6969 cr21.3%32.0%0.0x
2021-0964.2x₹6969 cr21.3%32.0%0.0x
2021-0869.2x₹6969 cr21.3%32.0%0.0x
2021-0765.6x₹6969 cr21.3%32.0%0.0x
2021-0659.0x₹6969 cr21.3%32.0%0.0x
2021-0580.9x₹5394 cr18.8%25.0%0.0x
2021-0478.3x₹5394 cr18.8%25.0%0.0x
2021-0369.9x₹5394 cr18.8%25.0%0.0x
2021-0264.9x₹5394 cr18.8%25.0%0.0x
2021-0165.0x₹5394 cr18.8%25.0%0.0x
2020-1274.1x₹5394 cr18.8%25.0%0.0x
2020-1169.5x₹5394 cr18.8%25.0%0.0x
2020-1060.6x₹5394 cr18.8%25.0%0.0x
2020-0958.8x₹5394 cr18.8%25.0%0.0x
2020-0860.2x₹5394 cr18.8%25.0%0.0x
2020-0750.5x₹5394 cr18.8%25.0%0.0x
2020-0644.0x₹5394 cr18.8%25.0%0.0x
2020-0546.9x₹4946 cr19.4%29.0%0.0x
2020-0445.8x₹4946 cr19.4%29.0%0.0x
2020-0339.0x₹4946 cr19.4%29.0%0.0x
2020-0241.3x₹4946 cr19.4%29.0%0.0x
2020-0138.3x₹4946 cr19.4%29.0%0.0x
2019-1236.2x₹4946 cr19.4%29.0%0.0x
2019-1135.1x₹4946 cr19.4%29.0%0.0x
2019-1034.4x₹4946 cr19.4%29.0%0.0x
2019-0932.7x₹4946 cr19.4%29.0%0.0x
2019-0831.9x₹4946 cr19.4%29.0%0.0x
2019-0732.1x₹4946 cr19.4%29.0%0.0x
2019-0631.3x₹4946 cr19.4%29.0%0.0x
2019-0548.2x₹3891 cr14.8%22.0%0.0x
2019-0452.9x₹3891 cr14.8%22.0%0.0x
2019-0351.5x₹3891 cr14.8%22.0%0.0x
2019-0250.1x₹3891 cr14.8%22.0%0.0x
2019-0145.6x₹3891 cr14.8%22.0%0.0x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback